Dyne Therapeutics (NASDAQ:DYN) Reaches New 1-Year Low – Time to Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) reached a new 52-week low on Saturday . The company traded as low as $14.79 and last traded at $15.87, with a volume of 9825974 shares. The stock had previously closed at $23.05.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on DYN shares. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Price Performance

The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -4.46 and a beta of 1.16. The business has a 50 day simple moving average of $27.29 and a 200-day simple moving average of $34.15.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the sale, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the transaction, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. The trade was a 19.19 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,742 shares of company stock valued at $1,443,246. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics in the third quarter valued at $34,000. Point72 DIFC Ltd acquired a new stake in Dyne Therapeutics in the third quarter valued at $36,000. US Bancorp DE grew its position in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the period. Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth about $62,000. Finally, KBC Group NV lifted its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.